Phosphorus magnetic resonance (MR) spectroscopy allows noninvasive measurement of phosphate-containing compounds and pH within brain cells. The authors obtained localized phosphorus MR spectra from 10 normal brains, four low-grade astrocytomas, six glioblastomas, four meningiomas, and three pituitary adenomas and found differences in the spectra of each tumor type. Compared to normal brain, the spectra from low-grade astrocytomas showed a significant reduction of the phosphodiester (PDE) peak. Glioblastomas were characterized by a significant reduction of the PDE peak, elevation ef the phosphomonoester (PME) peak, and a relatively alkaline intracellular pH. The spectra from meningiomas and pituitary adenomas were markedly different from the glial tumors. Meningiomas showed significant reductions in phosphocreatine, PDE, and inorganic phosphate, as well as a relatively alkaline pH. Pituitary adenomas resembled meningiomas, but had a much higher PME peak.
T
HE in vivo imaging of brain tumors can be performed with computerized tomography (CT), angiography, proton magnetic resonance (MR) imaging, and positron emission tomography (PET). Excellent anatomical localization can be obtained from CT, angiography, and MR imaging. Tumor edema can be appreciated from CT and MR studies, whereas tumor metabolism has until now been shown exclusively by PET. Phosphorus MR spectroscopy allows noninvasive characterization of phosphate-containing compounds within tumor cells and determination of the energy state and intracellular pH of brain tumors. ''2 4,7,13,15,16 Phosphorus MR spectroscopy of tumor cell cultures, excised fragments, and implanted animal tumors has shown that the phosphorus spectra of tumors is different from normal tissue and varies depending on the tumor type)
We have obtained localized phosphorus MR spectra from 10 normal brains, four low-grade astrocytomas, six glioblastomas, four meningiomas, and three pituitary adenomas. The spectra associated with each tumor type differ, and therefore can aid in the preoperative diagnosis of these tumors as well as provide a baseline for assessing the effects of various forms of antitumor therapy.
Clinical Material and Methods
Magnetic resonance spectra were obtained before any surgical intervention or therapy was initiated. This is important, as treatment is known to alter tumor metabolism. Histological verification of the diagnosis was obtained in all cases.
Magnetic Resonance Imaging and Spectroscopy
Combined MR imaging and spectroscopy was performed on a 1.5-tesla Philips Gyroscan. Magnetic field homogeneity was optimized using the proton signal from the head. Phosphorus spectra were obtained with a phosphorus-tuned headcoil placed inside the usual proton imaging headcoil. Immediately after a multi-slice proton MR image had been obtained in at least two planes to determine the location of the tumor, a phosphorus MR spectrum was acquired without moving the patient or repositioning the coils. The spectrum originated from a box-shaped volume of interest which was selected using a modification of the image-selected in vivo spectroscopy (ISIS) technique as first described by Ordidge, et al. ~4 The repetition time for the ISIS sequence was set at 3 seconds which is a compromise between maximum signal-to-noise ratio and minimum T,-weighting of the spectra. Spectra were acquired using a spectral width of 3000 Hz, 1024 data points, and 512 to 640 signal averages. The position of the box and dimensions in the anteroposterior, craniocaudal, and left-right axes were carefully chosen based on review of the infused CT scan and MR image. The average volume size was 102 cc (range 41 to 220 cc). Every attempt was made to exclude from the total volume both normal tissue and peritumoral tissue having little or no tumor but having an abnormal MR appearance due to edema. The volume chosen was superimposed on all relevant MR slices in at least two planes to eliminate any uncertainty as to what was included in the "corners" of the volume, and so that the size and shape of the volume could be adjusted to include a minimum of nr tissue (rather than a maximum of tumor). This, of course, meant that only very large tumors were eligible for study. However, we believe that this approach was important in establishing tumor-specific spectral characteristies.
Data Quantitation
The area of each of the resonances (peaks) in the phosphorus spectrum is proportional to the amount of any metabolite resonating at that frequency. However, there are major obstacles to obtaining absolute quantitation in vivo. First, the rapid pulsing, used to maximize the signal-to-noise ratio, results in resonance intensities being partially saturated in proportion to their T~-weighting (which may not be the same in pathological tissue as in normal tissue). Second, determining the area under each of the peaks in a brain spectrum is difficult due to the presence of overlapping peaks of uncertain line-width on the downfield side of the spectrum. In the absence of a satisfactory solution to the problem of absolute quantitation, a simple empirical method of quantitation was used in which spectra were processed in a standard way and peak intensities were then measured from an appropriately drawn baseline. The standard process consisted of the following: l) removing broad components of the spectrum by a lowfrequency background subtraction equivalent to subtracting an 80-Hz broadened version of the spectrum from itself (a convolutional difference); 2) filtering noise by multiplying the free induction decay (FID) by a function resulting in 15-Hz gaussian line-broadening in the spectrum; 3) Fourier transformation of the FID; and 4) phase correction of the final spectrum. This method of quantitation is dependent on shim quality; however, it yields reproducible values for control data in which the standard deviation of peak intensities relative to c~-adenosine triphosphate (ATP) varies by
FIG. I. Proton magnetic resonance (MR) image (left)
and phosphorus MR spectrum (right) of normal brain at 1.5 tesla. Each measurement in the phosphorus MR spectrum was obtained in the plane of the slice from brain tissue delineated by the box shown h'j? and processed as described in the text. PME = phesphomonoesters, P~ = inorganic phosphate, PDE = phosphodiesters, PCr = phosphocreatine, ATP = adenosine triphosphate. 7.02t * Data for normal brain are expressed as means _+ standard deviations. PME = phosphomonoester; P~ = inorganic phosphate; PDE = phosphodiester; PCr = phosphoereatine; pH~ = inlracellular pH. Significance of difference from normal brain: t = p < 0.001; ~ = p < 0.01; w = p < 0.02; 11 = P < 0.05. less than 10% of the mean for each peak. Other sources of error due to the method of volume selection, partial volume effects, and uncertainties about the margins of glial tumors are likely to be more important.
Intracellular pH was determined from the position of the inorganic phosphate (Pi) peak 'z relative to the phosphocreatine (PCr) peak, using a standard titration curve 5 where pH = 6.75 + log ((Pi shift -3.29)/(5.70 -Pi shift)).
R e s u l t s
The typical spectrum of normal brain (Fig. 1) consists of seven peaks corresponding to phosphomonoesters (PME's), P~, phosphodiesters (PDE's), PCr, -y-ATP, c~-ATP, and I3-ATP. With shimming and processing of the FID, as described above, the normal height of the PCr peak is about twice that of the adjacent 7-ATP peak. The PDE peak is of similar height, while the P, and PME peaks are progressively lower. Normal intracellular pH determined from peak positions in spectra processed as described is about 6.95, which is substantially lower than extracellular pH. Table 1 shows the peak intensities of phosphorus-containing compounds as well as the intracellular pH of normal brain and the most common intracranial tumors.
Four patients with low-grade astrocytomas (grade I-II, Kernohan classification) 8 were studied. Figure 2 shows the proton image from one of these patients together with the volume of interest around the tumor and its phosphorus spectrum. The mean relative peak heights and intracellular pH for all four patients are shown in Table 1 . Prosphorus spectra of low-grade gliomas tended to look like normal brain. The only significant difference, on average, was a reduction of the PDE peak intensity. Intracellular pH was higher than normal in some tumors but this was not a statistically significant characteristic of the group.
A representative tumor and phosphorus spectrum hG. 3. Proton magnetic resonance (MR) image (left) and phosphorus MR spectrum (right) of a glioblastoma. The main differences from normal brain are the high phosphomonoester (PME) peak and the high intracellular pH (see Table 1 ). The phosphodiester (PDE) peak is not low in this example. The volume of interest is indicated by the box shown left. See Fig. 1 legend for definitions of the abbreviations. from one of the six glioblastomas is shown in Fig. 3 . Mean relative peak heights and intracellular pH are shown in Table l . In addition to a significant reduction of PDE, glioblastoma specimens showed an increase in PME's and intracellular pH with respect to normal brain. When specimens of low-and high-grade astrocytomas were compared, the differences in peak heights of phosphorus-containing compounds were not significant in the small number of specimens available.
The proton image and phosphorus spectrum from a meningioma specimen is shown in Fig. 4 and peak heights and intracellular pH are found in Table 1 . There was a marked difference between these spectra and normal brain. Meningiomas were characterized by large reductions of PCr and PDE's and very alkaline tumor intracellular pH. Although the P~ peak height was also reduced, this may be accounted for by the marked decrease in PDE height.
Three patients with large suprasellar pituitary adenomas were studied, two with pro[actinomas and one with an oncocytoma (Fig. 5 and Table 1 ). Pituitary adenomas also had a distinctive spectrum characterized by a uniquely high PME peak in addition to other metabolite changes similar to meningiomas, that is, low PCr and PDE, an apparently low Pi peak, and a high intracellular pH.
Discussion

Phosphorus Spectra of Tumors
The characteristic features of the four intracranial tumor types studied are summarized as follows. Lowgrade astrocytomas resembled normal brain except for a slight reduction on average in their PDE peak. Glioblastomas, in addition, had a higher PME peak and were more alkalotic than normal brain. The spectra from meningiomas and pituitary adenomas differed markedly from normal brain and the glial tumors, perhaps consistent with their different cellular composition. Meningiomas had low PCr, PDE, and P~ peaks. Pituitary adenomas were similar to meningiomas but had, in addition, a dominant PME peak. All tumors except low-grade astrocytornas had a relatively alkalotic pH.
There are only a few reports of human brain tumors studied in vivo by phosphorus MR spectroscopy. ~'z4' 7.~3.15.s6.~ Because of differences in methods of quantitation of phosphorus-containing compounds and determination of volume of interest between other studies and ours, only qualitative comparison is possible. The finding of elevated pH in tumors and decreased PCr in meningiomas and prolactinomas is in agreement with our series. We observed an apparently decreased P~ in meningiomas, but the quantitation of P~ by peak height is subject to large errors secondary to changes in PDE's. However, reduced Pi has been found in excised meningioma specimens by Lowry, et al. ~o While the mean height of the PCr peak in the glioblastomas in our patients did not differ from normal, this peak showed the most variability. The difficulty in delineating the tumor edge from normal brain may be in part responsible for the high level of PCr we observed in gliomas. High PME levels have been recorded in carcinomas ~3 and we found the same in pituitary adenomas. This may reflect similarities in tissue origins and may be the most reliable feature differentiating these tumors from glial tissue.
Phosphomonoesters and Phosphodiesters
The composition of each peak of the phosphorus spectrum of brain has been previously determined. 6 The PME peak is composed of phosphorylcholine, phosphorylethanolamine, and ribose-5-phosphate, each an important compound in cell membrane structure and synthesis. The PDE peak consists primarily of glycerophosphorylcholine and glycerophosphorylethanolamine which are products of membrane catabolism. Therefore, an increased PME concentration combined with decreased PDE levels could indicate a shift toward membrane synthesis and tumor growth. We found pituitary adenomas and glioblastomas to have the highest levels of PME and lower PDE levels, which is consistent with their higher rate of growth. In contrast, low-grade astrocytomas, which have the slowest growth rate, ~7 had the lowest PME levels. Other investigators have found high PME levels in developing neonatal brain and rapidly growing neuroblastoma. L~
Inferences About ('elhdar Energy State
The levels of PCr, P~, and ATP in cells have been used to assess acute changes in energy state. The PCr:ATP and PCr:P, ratios were decreased in pituitary adenomas and meningiomas and relatively unchanged for glial tumors. Unlike acute changes in ratios of highand low-energy phosphate compounds, the ratios in tumors mainly reflect different creatine pools. Lowry, et al., 1~ found the creatine levels in excised human meningiomas to be only 25% that of normal brain, while the levels in gliomas ranged from 15% to 86%. We have found similar results by enzymatic assay of tumor tissue excised at operation. The total ereatine pool in meningiomas was 17% to 60% that of normal brain. One pituitary adenoma had 43% of control creatine concentrations. Glioblastomas were most variable with 33% to 86% of the creatine compared to normal brain. An acute decrease in PCr concentration has been observed in cerebral tumors after chemotherapy 1-~ and radiotherapy. 3 Such acute changes are likely to represent a reduction in energy state of phosphatecontaining metabolites and may be useful in observing the response of the tumor to treatment.
Observations of Glioma Spectra
As a group, the glioblastomas in this study showed the widest variability in their spectra. One possible explanation is the difficulty in distinguishing a sharp tumor-brain interface on MR images which can result in contamination of the tumor spectrum by signal from edematous or normal brain. The meningiomas and pituitary adenomas used for the analysis were all large and well circumscribed so as to allow easy selection of tumor volume for spectroscopy that did not include adjacent brain tissue.
Reduced PCr, high E, and decreased pH levels are characteristics of ischemic tissue. ~ While five of the six glioblastomas in this study had CT and operative features usually ascribed to intratumoral necrosis, none had spectra suggestive of ischemia. Similar findings were reported by Oberhaensli, el al. z3 The reason for this is unclear. It may be an artifactual finding reflecting either the large volumes used for spectroscopy or the inclusion of normal tissue in the volume selected. Alternatively, viable macrophages and inflammatory cells do exist in the necrotic portion of the tumoP ~ and dead cells are cleared away. This may explain the lack of evidence for substantial dead tissue in the overall spectrum.
Conclusions
The major primary brain tumors --gliomas, meningiomas, and pituitary adenomas --have different MR spectra. In addition to revealing certain metabolic and growth characteristics of intracranial tumors itt vivo, these spectra can contribute to an accurate preoperative differential diagnosis. This has been useful in our experience in the differential diagnosis of midline subfrontal tumors, where the distinction between meningiomas and pituitary adenomas is often difficult, particularly if the latter are nonsecreting. Also, because glial tumors and carcinomas appear to have different spectra, large cortical metastatic tumors could possibly be differentiated from glioblastomas.
More experience is needed to establish a catalog of phosphorus-containing compounds in various intracranial tumors. In addition, the ability to select smaller volumes and obtain spectra with an improved signalto-noise ratio will allow better comparison between poorly defined glial tumors, normal brain, and other intracrania[ tumors.
